Replies to post #105330 on Biotech Values

[xrymd]

What do you make of the abstract I linked to?

Its a retrospective study which are interesting for further study but thats about it. I don't know the journal per se as to the quality of the manuscripts. This to me seems like case where the literature doesn't seem to mimic the general clinical experience. I will ask several cardiac anesthetistsfor there opinion if you like.

The amount of protamine used in CV surgery is very small compared to its overall use. Dialysis , cardiac and peripheral angiography, non-cardiac vascular surgery. I doubt with bundled dialysis payments there will be much incentive to spend $$ on heparin reversal.

The half life of heparin is about 45 minutes so generally you wait an hour and the problem takes care of it self without the use of protamine.

[xrymd]

I've spoken with a small handful of docs unconnected to pymx and all said the opposite of you on both thrombin and Protamine.

FWIW I spoke to the chief of cardiovascular surgery (in the MD's cafeteria) and also to cardiac anesthesia. Both couldn't even remember a significant protamine reaction. They said protamine is simple to use so they doubted it would be replaced. There may be a statistical benefit to this new drug which may not be clinically relevant. Time will tell.

PYMX may be a good for a trade but unless they have some other "great" product long term sucess to would seem to be doubtful. Building a sales force to replace a dirt cheap drug doesn't seem to promising.